Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
(no author information available yet)
No abstract text is available yet for this article.
July 8, 2019: Lancet Neurology
#2
REVIEW
Kaibin Shi, De-Cai Tian, Zhi-Guo Li, Andrew F Ducruet, Michael T Lawton, Fu-Dong Shi
Stroke, including acute ischaemic stroke and intracerebral haemorrhage, results in neuronal cell death and the release of factors such as damage-associated molecular patterns (DAMPs) that elicit localised inflammation in the injured brain region. Such focal brain inflammation aggravates secondary brain injury by exacerbating blood-brain barrier damage, microvascular failure, brain oedema, oxidative stress, and by directly inducing neuronal cell death. In addition to inflammation localised to the injured brain region, a growing body of evidence suggests that inflammatory responses after a stroke occur and persist throughout the entire brain...
July 8, 2019: Lancet Neurology
#3
Ari J Green
No abstract text is available yet for this article.
July 5, 2019: Lancet Neurology
#4
Diego Cadavid, Michelle Mellion, Raymond Hupperts, Keith R Edwards, Peter A Calabresi, Jelena Drulović, Gavin Giovannoni, Hans-Peter Hartung, Douglas L Arnold, Elizabeth Fisher, Richard Rudick, Sha Mi, Yi Chai, Jie Li, Yiwei Zhang, Wenting Cheng, Lei Xu, Bing Zhu, Susan M Green, Ih Chang, Aaron Deykin, Sarah I Sheikh
BACKGROUND: Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that opicinumab treatment might enhance remyelination in patients with CNS demyelinating diseases. We aimed to assess the safety and efficacy of opicinumab in patients with relapsing multiple sclerosis. METHODS: We did a randomised, double-blind, placebo-controlled, dose-ranging, phase 2 study (SYNERGY) at 72 sites in 12 countries...
July 5, 2019: Lancet Neurology
#5
REVIEW
Stewart A Factor, Pierre R Burkhard, Stanley Caroff, Joseph H Friedman, Connie Marras, Michele Tinazzi, Cynthia L Comella
A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people...
July 3, 2019: Lancet Neurology
#6
Stoyan Popkirov, David M Baguley, Alan J Carson, Richard J Brown, Jon Stone
No abstract text is available yet for this article.
July 3, 2019: Lancet Neurology
#7
Kathleen E Bachynski, James M Smoliga
No abstract text is available yet for this article.
July 3, 2019: Lancet Neurology
#8
Amanda I Adler, Helen Knight
No abstract text is available yet for this article.
July 3, 2019: Lancet Neurology
#9
Jonathan Blott
No abstract text is available yet for this article.
July 2, 2019: Lancet Neurology
#10
Johannes Levin, Sylvia Maaß, Madeleine Schuberth, Armin Giese, Wolfgang H Oertel, Werner Poewe, Claudia Trenkwalder, Gregor K Wenning, Ulrich Mansmann, Martin Südmeyer, Karla Eggert, Brit Mollenhauer, Axel Lipp, Matthias Löhle, Joseph Classen, Alexander Münchau, Jan Kassubek, Florin Gandor, Daniela Berg, Silvia Egert-Schwender, Cornelia Eberhardt, Friedemann Paul, Kai Bötzel, Birgit Ertl-Wagner, Hans-Jürgen Huppertz, Ingrid Ricard, Günter U Höglinger
BACKGROUND: Multiple system atrophy is a rare neurodegenerative disease characterised by aggregation of α-synuclein in oligodendrocytes and neurons. The polyphenol epigallocatechin gallate inhibits α-synuclein aggregation and reduces associated toxicity. We aimed to establish if epigallocatechin gallate could safely slow disease progression in patients with multiple system atrophy. METHODS: We did a randomised, double-blind, parallel group, placebo-controlled clinical trial at 12 specialist centres in Germany...
June 27, 2019: Lancet Neurology
#11
Maria Stamelou
No abstract text is available yet for this article.
June 27, 2019: Lancet Neurology
#12
Katharina A Schindlbeck, David Eidelberg
No abstract text is available yet for this article.
June 19, 2019: Lancet Neurology
#13
Heather Wilson, George Dervenoulas, Gennaro Pagano, Christos Koros, Tayyabah Yousaf, Marina Picillo, Sotirios Polychronis, Athina Simitsi, Beniamino Giordano, Zachary Chappell, Benjamin Corcoran, Maria Stamelou, Roger N Gunn, Maria Teresa Pellecchia, Eugenii A Rabiner, Paolo Barone, Leonidas Stefanis, Marios Politis
BACKGROUND: Because of the highly penetrant gene mutation and clinical features consistent with idiopathic Parkinson's disease, carriers of the autosomal dominant Ala53Thr (A53T; 209G→A) point mutation in the α-synuclein (SNCA) gene are an ideal population to study the premotor phase and evolution of Parkinson's pathology. Given the known neurochemical changes in the serotonergic system and their association with symptoms of Parkinson's disease, we hypothesised that carriers of the A53T SNCA mutation might show abnormalities in the serotonergic neurotransmitter system before the diagnosis of Parkinson's disease, and that this pathology might be associated with measures of Parkinson's burden...
June 19, 2019: Lancet Neurology
#14
Anthony Feinstein
No abstract text is available yet for this article.
June 14, 2019: Lancet Neurology
#15
Hatice Kurucu, Tara Spires-Jones, Colin Smith
No abstract text is available yet for this article.
June 12, 2019: Lancet Neurology
#16
Victor L Villemagne, Vincent Doré, Samantha Burnham
No abstract text is available yet for this article.
June 11, 2019: Lancet Neurology
#17
Peter Ranscombe
No abstract text is available yet for this article.
June 10, 2019: Lancet Neurology
#18
Peter Ranscombe
No abstract text is available yet for this article.
June 7, 2019: Lancet Neurology
#19
Song Li, Weidong Le
No abstract text is available yet for this article.
June 7, 2019: Lancet Neurology
#20
REVIEW
Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Christine Klein, Louis C S Tan, Raymond L Rosales, Roongroj Bhidayasiri, Yih-Ru Wu, Hui-Fang Shang, Andrew H Evans, Pramod K Pal, Nobutaka Hattori, Chong Tin Tan, Beomseok Jeon, Eng-King Tan, Anthony E Lang
1·8 billion people of diverse ethnicities and cultures live in the Western Pacific Region. The increasing longevity of populations in this region is a major contributor to the exponential increase in Parkinson's disease prevalence worldwide. Differences exist between Parkinson's disease in the Western Pacific Region and in Europe and North America that might provide important insights into our understanding of the disease and approaches to management. For example, some genetic factors (such as LRRK2 mutations or variants) differ, environmental exposures might play differential roles in modulating the risk of Parkinson's disease, and fewer dyskinesias are reported, with some differences in the profile of non-motor symptoms and comorbidities...
June 4, 2019: Lancet Neurology
Fetching more papers... 
